Pediatric High-Risk Deep Venous Thrombosis Lytic Outcomes Trial

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 31, 2018

Primary Completion Date

April 30, 2023

Study Completion Date

June 30, 2023

Conditions
Deep Vein ThrombosisPost-Thrombotic SyndromeVenous Thrombosis
Interventions
DRUG

Recombinant tissue plasminogen activator (rt-PA)

Catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.

DRUG

Standard Anticoagulation Therapy

Standard anticoagulation determined by physician for a period of 3-6 months

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

RTI International

OTHER

collaborator

Mid America Heart Institute

OTHER

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

Genentech, Inc.

INDUSTRY

lead

University of Colorado, Denver

OTHER